---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-019073"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T15:00:47.844295+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics announces 2023 annual meeting voting results; directors elected, auditor ratified

## Summary
- 4,469,519 shares (~53% of outstanding) represented at May 25, 2023 meeting.
- William B. Hayes (2,452,279 for) and Anthony Maddaluna (2,544,652 for) elected as Class II directors.
- Ratification of Haskell & White LLP as auditor for FY2023: 4,446,392 for, 22,167 against, 960 abstain.

## SEC filing metadata
- accession: 0001493152-23-019073
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/0001493152-23-019073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-019073
- JSON: https://secwatch.observer/filing/0001493152-23-019073.json
- Plain text: https://secwatch.observer/filing/0001493152-23-019073.txt

## Key facts
- Shareholder Votes
  Indaptus Therapeutics, Inc. shareholders approved Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Proposal 2. Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/0001493152-23-019073-index.htm
- Shareholder Votes
  Indaptus Therapeutics, Inc. shareholders approved Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal. at the 2023-05-25 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: Proposal 1 . Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223019073/0001493152-23-019073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.